Malbec O, Schmitt C, Bruhns P, Krystal G, Fridman W H, Daëron M
Laboratoire d'Immunologie Cellulaire et Clinique, INSERM U.255, Institut Curie, 75005 Paris, France.
J Biol Chem. 2001 Aug 10;276(32):30381-91. doi: 10.1074/jbc.M011094200. Epub 2001 May 18.
We previously found that low affinity receptors for the Fc portion of IgG, FcgammaRIIB, which are widely expressed by hematopoietic cells, can negatively regulate receptor tyrosine kinase-dependent cell proliferation. We investigated here the mechanisms of this inhibition. We used as experimental models wild-type mast cells, which constitutively express the stem cell factor receptor Kit and FcgammaRIIB, FcgammaRIIB-deficient mast cells reconstituted with wild-type or mutated FcgammaRIIB, and Src homology 2 domain-containing inositol polyphosphate 5-phosphatase 1 (SHIP1)-deficient mast cells. We found that, upon coaggregation with Kit, FcgammaRIIB are tyrosyl-phosphorylated, recruit SHIP1, but not SHIP2, SH2 domain-containing protein tyrosine phosphatase-1 or -2, abrogate Akt phosphorylation, shorten the duration of the activation of mitogen-activated protein kinases of the Ras and Rac pathways, abrogate cyclin induction, prevent cells from entering the cell cycle, and block thymidine incorporation. FcgammaRIIB-mediated inhibition of Kit-dependent cell proliferation was reduced in SHIP1-deficient mast cells, whereas inhibition of IgE-induced responses was abrogated. Cell proliferation was, however, inhibited by coaggregating Kit with FcgammaRIIB whose intracytoplasmic domain was replaced with the catalytic domain of SHIP1. These results demonstrate that FcgammaRIIB use SHIP1 to inhibit pathways shared by receptor tyrosine kinases and immunoreceptors to trigger cell proliferation and cell activation, respectively, but that, in the absence of SHIP1, FcgammaRIIB can use other effectors that specifically inhibit cell proliferation.
我们先前发现,造血细胞广泛表达的IgG Fc段低亲和力受体FcγRIIB可负向调节受体酪氨酸激酶依赖性细胞增殖。我们在此研究了这种抑制作用的机制。我们使用野生型肥大细胞作为实验模型,其组成性表达干细胞因子受体Kit和FcγRIIB;用野生型或突变型FcγRIIB重建的FcγRIIB缺陷型肥大细胞;以及含Src同源2结构域的肌醇多磷酸5-磷酸酶1(SHIP1)缺陷型肥大细胞。我们发现,与Kit共聚集后,FcγRIIB发生酪氨酸磷酸化,募集SHIP1,但不募集SHIP2、含SH2结构域的蛋白酪氨酸磷酸酶-1或-2,消除Akt磷酸化,缩短Ras和Rac途径的丝裂原活化蛋白激酶激活持续时间,消除细胞周期蛋白诱导,阻止细胞进入细胞周期,并阻断胸苷掺入。在SHIP1缺陷型肥大细胞中,FcγRIIB介导的对Kit依赖性细胞增殖的抑制作用减弱,而对IgE诱导反应的抑制作用则被消除。然而,通过将Kit与胞质结构域被SHIP1催化结构域取代的FcγRIIB共聚集,细胞增殖受到抑制。这些结果表明,FcγRIIB利用SHIP1抑制受体酪氨酸激酶和免疫受体分别触发细胞增殖和细胞激活所共有的途径,但在缺乏SHIP1的情况下,FcγRIIB可利用其他特异性抑制细胞增殖的效应分子。